The Prognostic Significance of Serum Lactate Dehydrogenase to Albumin Ratio in Pancreatic Ductal Adenocarcinoma

IF 0.3 4区 医学 Q4 Medicine Acta Medica Mediterranea Pub Date : 2023-04-07 DOI:10.32552/2023.actamedica.819
H. Bilge, Ö. Başol, B. Demir, A. Oğuz
{"title":"The Prognostic Significance of Serum Lactate Dehydrogenase to Albumin Ratio in Pancreatic Ductal Adenocarcinoma","authors":"H. Bilge, Ö. Başol, B. Demir, A. Oğuz","doi":"10.32552/2023.actamedica.819","DOIUrl":null,"url":null,"abstract":"Objective: This study was performed to investigate the prognostic role of lactate dehydrogenase/albumin ratio (LAR) and pancreatic ductal adenocarcinoma (PDAC) with initial curable resection treatment.\nMaterials and Methods: This retrospective study was conducted with the data of patients with resectable PDAC. The (ROC) analysis showed that the optimal sill value for pretreatment LAR was 91.43 and this threshold value was used in other analyses. Univariate and multivariate analyses were performed to determine the prognostic factors for overall survival (OS).\nResults: Our study consisted of 70 patients with a mean age of 59.5±13.2 years and 37 (52,9%) women. OS was 50 months in LAR <91.43 (n = 32) patients and 27,7 months in LAR≥91.43 (n=38) patients, respectively. Kaplan–Meier curves showed that LAR≥91.43 was significantly associated with worse OS (p=0.029). Multivariate analyses proved that LAR was an independent predictor in resectable PDAC patients (p=0.017).\nConclusion: Our results showed that a high pre-treatment LAR level was a unfavorable prognosticator in PDAC patients undergoing curative resection. LAR has the potential to be a prognostic biomarker in clinical practice.","PeriodicalId":50891,"journal":{"name":"Acta Medica Mediterranea","volume":"44 1","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Medica Mediterranea","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32552/2023.actamedica.819","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This study was performed to investigate the prognostic role of lactate dehydrogenase/albumin ratio (LAR) and pancreatic ductal adenocarcinoma (PDAC) with initial curable resection treatment. Materials and Methods: This retrospective study was conducted with the data of patients with resectable PDAC. The (ROC) analysis showed that the optimal sill value for pretreatment LAR was 91.43 and this threshold value was used in other analyses. Univariate and multivariate analyses were performed to determine the prognostic factors for overall survival (OS). Results: Our study consisted of 70 patients with a mean age of 59.5±13.2 years and 37 (52,9%) women. OS was 50 months in LAR <91.43 (n = 32) patients and 27,7 months in LAR≥91.43 (n=38) patients, respectively. Kaplan–Meier curves showed that LAR≥91.43 was significantly associated with worse OS (p=0.029). Multivariate analyses proved that LAR was an independent predictor in resectable PDAC patients (p=0.017). Conclusion: Our results showed that a high pre-treatment LAR level was a unfavorable prognosticator in PDAC patients undergoing curative resection. LAR has the potential to be a prognostic biomarker in clinical practice.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
血清乳酸脱氢酶与白蛋白比值对胰腺导管腺癌预后的意义
目的:探讨乳酸脱氢酶/白蛋白比值(LAR)和胰导管腺癌(PDAC)在初始可治愈切除治疗中的预后作用。材料与方法:回顾性研究可切除PDAC患者的资料。(ROC)分析显示,预处理LAR的最佳阈值为91.43,该阈值可用于其他分析。进行单因素和多因素分析以确定总生存期(OS)的预后因素。结果:我们的研究包括70例患者,平均年龄为59.5±13.2岁,其中37例(52.9%)为女性。LAR <91.43 (n= 32)例患者的OS为50个月,LAR≥91.43 (n=38)例患者的OS为27.7个月。Kaplan-Meier曲线显示LAR≥91.43与较差的OS显著相关(p=0.029)。多变量分析证明LAR是可切除PDAC患者的独立预测因子(p=0.017)。结论:我们的研究结果表明,在接受根治性切除的PDAC患者中,高治疗前LAR水平是一个不利的预后因素。在临床实践中,LAR有可能成为一种预后生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Acta Medica Mediterranea
Acta Medica Mediterranea 医学-医学:内科
自引率
0.00%
发文量
0
审稿时长
6-12 weeks
期刊介绍: Acta Medica Mediterranea is an indipendent, international, English-language, peer-reviewed journal, online and open-access, designed for internists and phisicians. The journal publishes a variety of manuscript types, including review articles, original research, case reports and letters to the editor.
期刊最新文献
Older patients’ driving safety with the help of DRIVING SIMULATOR: Which cognitive test can predict better driving safety? Evaluation of the results of intra-articular platelet-rich plasma injections in patients with knee osteoarthritis Low-grade glial tumors: The experience of an oncology hospital in Türkiye High 30-day readmission rates in hospitalized patients with heart failure: Strengthening the need for a multidisciplinary and integrated approach Malignancy and Sarcoidosis: A Single Center Experience from Turkey
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1